Book a demo

Chemical intelligence powered by cypris.ai

Quercitrin

2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one · also: Thujin · Usaf cf-2 · Quercetrin · Quercimelin · quericitrin · Quercitroside

FormulaC21H20O11
Mol. weight448.38
PubChem CID5280459
InChIKeyOXGUCUVFOIWWQJ-HQBVPOQASA-N
SMILESC[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC(=C(C=C4)O)O)O)O)O
7,657Patents
419Research papers
780Patents - last 3 years
19Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#AssigneePatents
1Symrise AG384
2British American Tobacco PLC289
3L'Oréal SA77
4Maxingvest AG62
5Teva Pharmaceutical Industries Ltd61
6Cargill Inc45
7BASF SE43
8Novo Nordisk Fonden42
9Sumitomo Rubber Industries Ltd41
10Kose Corp39

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#CodeAreaPatents
1A61KMedicinal preparations3,820
2A61PTherapeutic activity (drug indications)2,232
3A61QCosmetics, personal care1,451
4A23LFoods and beverages (general)1,249
5A23VFoods, foodstuffs - indexing scheme854
6G01NInvestigating / analysing materials391
7A24B350
8C07DHeterocyclic compounds329
9Y02AClimate change adaptation289
10A01NPreservation of bodies; biocides; pest repellents268

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Representative patents

The filings that best characterise the patent activity around this compound, most-referenced first.

TitleYearAssigneeCited by
Application of quercitrin in preparation of human gamma delta T cell proliferator20145
COSMETIC COMPOSITION COMPRISING QUERCITRIN AND/OR MYRICITRIN AS ACTIVE INGREDIENTS20105
Process of isolating quercitrin19505
A method of extracting quercitrin and Bergenin from ardisia japonica20183
A method of extracting ardisin and quercitrin from ardisia japonica20183

How research activity has moved

Papers published per year for this compound, over the last decade of indexed records.

YearPapers
201619
201722
201819
201914
20209
20218
20225
202310
20247
20252

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#AuthorAffiliationPapers
1Lin ZhengGuiyang Medical University6
2Jairo Kenupp BastosUniversidade de São Paulo5
3Marta MonjoResearch Institute of Health Sciences5
4Joana Maria RamisResearch Institute of Health Sciences5
5Michelle Frazão MuzitanoUniversidade Federal do Rio de Janeiro4
6Bartira Rossi‐BergmannUniversidade Federal do Rio de Janeiro4
7Valdimaras JanulisLithuanian University of Health Sciences4
8Sônia Soares CostaUniversidade Federal do Rio de Janeiro4
9Laurian VlaseIuliu Hațieganu University of Medicine and Pharmacy3
10Denise Crispim TavaresUniversidade de Franca3

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular composition of quercitrin?

Quercitrin has the molecular formula C21H20O11 and a molecular weight of 448.38. Its canonical IUPAC name is 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one, and it is also known as quercetin 3-rhamnoside or quercetin-3-O-rhamnoside.

Which organizations hold the most patents for quercitrin-related technologies?

Symrise AG leads with 384 patents, followed by British American Tobacco PLC with 289 patents. Other significant patent holders include L'Oréal SA with 77 patents, Maxingvest AG with 62 patents, and Teva Pharmaceutical Industries Ltd with 61 patents.

What research topics are most associated with quercitrin publications?

Highly-cited papers on quercitrin focus on phytochemicals and antioxidant activities. A prominent 2005 paper titled 'In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-κB pathway' has received 649 citations. Another 2019 paper examining quercetin and quercitrin's effects on inflammatory response and oxidative stress in LPS-induced RAW264.7 cells has garnered 290 citations.

What are the primary technical areas covered in quercitrin patents?

The largest share of quercitrin patents fall under CPC subclass A61K (pharmaceutical preparations) with 3820 patents, followed by A61P (medicinal preparation applications) with 2232 patents, and A61Q (cosmetics and personal care) with 1451 patents. Food and beverage applications are represented in A23L with 1249 patents.

How has patent activity for quercitrin evolved in recent years?

Patent activity for quercitrin has fluctuated over the past decade, with peak activity in 2018 (556 patents). From 2022 to 2025, activity shows 501 patents in 2022, 447 in 2023, 390 in 2024, and 43 patents filed in 2025. Overall, there were 780 patents filed in the last 3 years, while academic publications numbered 19 in that period.

Turn any compound into a complete chemical intelligence landscape

Go beyond static compound data. Cypris resolves identities, patents, papers, and commercial signals into one AI-powered view - so your team can move from a single chemical question to a complete R&D, IP, and market landscape.

Schedule a free trial